AbbvieABBV

01Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis for six months ended June 30, 2026 In April 2026, AbbVie announced the submission of an application to the U.S. FDA for Skyrizi for subcutaneous induction for the treatment of adult patients with moderately to severely active CD In June 2026, AbbVie announced the U.S. FDA approved Skyrizi for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis

02A deep mid- and late-stage pipeline concentrated in high-value therapeutic areas—including an explicit obesity program—positions AbbVie for diversified revenue streams beyond immunology, reducing single-franchise dependence over the next decade

03In January 2026, AbbVie announced a voluntary agreement with the U.S. government to further advance access and affordability of AbbVie's products in the U.S. while protecting and investing in U.S. pharmaceutical innovation Under this voluntary agreement, the U.S. government has agreed to provide AbbVie a three-year exemption from tariffs and future price mandates AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade

04Cash flows from operations of $7.3 billion for the six months ended June 30, 2026 Financing cash flows included cash dividend payments of $6.2 billion for the six months ended June 30, 2026 On June 18, 2026, the company announced that its board of directors declared a quarterly dividend of $1.73 per share In June 2026, Standard and Poor's Global Ratings affirmed AbbVie's senior unsecured long-term credit rating of A- and revised AbbVie's outlook to positive from stable